Bahar TASDELEN, Serkan GURGUL, Derya KARPUZ, Olgu HALLİOGLU, Belgin BUYUKAKİLLİ

Effects of bosentan, sildenafil and their combination on T-wave amplitude and QT ınterval in a rat model of pulmonary hypertension

Aim: Although, bosentan and sildenafil have been used to treat PAH, the effect of these drugs on electrocardiographic (ECG)changes are still unclear. The aim of this study is to evaluate the effects of bosentan, sildenafil, and their combination on T-waveamplitude and QT interval in rats with monocrotaline (MCT)-induced PAH.Materials and Methods: Saline (control) or MCT were applied to sixty-six male Wistar rats. By the development of PAH (4th week),MCT-given rats were randomized into 4 groups and were treated orally with bosentan, sildenafil and combination of sildenafil andbosentan or placebo for 3 weeks. Echocardiographic (ECHO) and ECG examinations were performed three times on baseline, 4thand 7th week.Results: ECHO results showed that the application of MCT developed PAH in all injected rats. Usually, T-wave changes and QTcprolongation in ECG began after PAH and T-wave amplitudes, T-repolarization time as well as QTc intervals significantly increasedin all groups after treatment (p

PDF

___

1.Bogaard HJ, Abe K, Vonk NA, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009;135(3):794-804.
2.Handoko ML, deMan FS, Happe CM, Schalij I, Musters RJ, Westerhof N, et al. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 2009;120(1):42-9.
3.Kaogler H, Hartmann O, Leineweber K, Nguyen van P, Schott P, Brodde OE, et al. Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. Circ Res 2003;93(3):230-7.
4.Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiolological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297(6):L1013-32.
5.Folino AF, Bobbo F, Schiraldi C, Tona F, Romano S, Buja G, et al. Ventricular arrhythmias and autonomic profile in patients with primary pulmonary hypertension. Lung 2003;181(6):321-8.
6.Henkens IR, Mouchaers KT, Vonk-Noordegraaf A, Boonstra A, Swenne CA, Maan AC, et al. Improved ECG detection of presence and severity of right ventricular pressure load validated with cardiac magnetic resonance imaging. Am J Physiol Heart Circ Physiol 2008;294(5):H2150-7.
7.Hong-liang Z, Qin L, Zhi-hong L, Zhi-hui Z, Chang-ming X, Xin-hai N, et al. Heart rate-corrected QT interval and QT dispersion in patients with pulmonary hypertension. Wien Klin Wochenschr 2009;121(9-10):330-3.
8.Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]: developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(19):e385-484.
9.Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R, et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 2013;167(3):669-76.
10.Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C, et al. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 2006;231(6):967-73.
11.McLaughin VV, Davis M, Cornwell W. Pulmonary arterial hypertension. Curr Probl Cardiol. 2011;36(12):461-517.
12.Hardziyenka M, Campian ME, Bruin-Bon HA, Michel MC, Tan HL. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr 2006;19(10):1272-9.
13.Kaddoura S, Firth JD, Boheler KR, Sugden PH, Poole-Wilson PA. Endothelin-1 is involved in norepineprine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 1996;93(11):2068-79.
14.Hassan MA, Ketat AF. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 2005;6:5-10.
15.Mouchaers KT, Schalij I, Versteilen AM, Hadi AM, van Nieuw Amerongen GP, van Hinsbergh VW, et al. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009;297(1):200-7.
16.Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med 2010;88(1):47-60.
17.van Wolferen SA, Marcus JT, Westerhof N, Spreeuwenberg MD, Marques KM, Bronzwaer JG, et al. Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J 2008;29(1):120-7.
18.Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009;120(20):1951-60.
19.Benoist D, Stones R, Drinkhill MJ, Benson AP, Yang Z, Cassan C, et al. Cardiac arrhythmia mechanisms in rats with heart failure induced by pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2012;302(11):2381-95.
20.Zhou S, Cao JM, Tebb ZD, Ohara T, Huang HL, Omichi C, et al. Modulation of QT interval by cardiac sympathetic nerve sprouting and the mechanisms of ventricular arrhythmia in a canine model of sudden cardiac death. J Cardiovasc Electrophysiol 2001;12(9):1068-73.
21.Schrier RW, Bansal S. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol 2008;3(5):1232-7.
22.Singer RB. Comparative mortality in asymptomatic men issued standard insurance with routine ECG classified as normal or with minor T wave changes. J Insur Med. 2008;40(3-4):186-90.
23.Arisha MM, Girerd N, Chauveau S, Bresson D, Scridon A, Bonnefoy E, et al. In-hospital heart rate turbulence and microwave t-wave alternans abnormalities for prediction of early life-threatening ventricular arrhythmia after acute myocardial infarction. Ann Noninvasive Electrocardiol 2013;18(6):530-7.
24.Yorikane R, Koike H, Miyake S. Electrophysiological effects of endothelin-1 on canine myocardial cells. J Cardiovasc Pharmacol 1991;17:159-62.
25.Duru F, Barton M, Lüescher TF, Candinas R, Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res 2001;49(2):272–80.
26.Garjani A, Wainwright CL, Zeitlin IJ, Wilson C, Slee J. Effects of endothelin-1 and the ETA-receptor antagonist, BQ123, on ischemic arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995;25(4):634-42.
27.Crockett TR, Sharif I, Kane KA, Wainwright CL. Sarafotoxin 6c protects against ischaemia-induced cardiac arrhythmias in vivo and in vitro in the rat. J Cardiovasc Pharmacol 2000;36(5 Suppl 1):297-9.
28.Oikonomidis DL, Tsalikakis DG, Baltogiannis GG, Tzallas AT, Xourgia X, Agelaki MG, et al. Endothelin-B receptors and ventricular arrhythmogenesis in the rat model of acute myocardial infarction. Basic Res Cardiol 2010;105(2):235-45.
29.Lee TM, Chen CC, Chung TH, Chang NC. Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts. Eur J Pharmacol 2012;690(1-3):124–32.